Fate Therapeutics, Inc.FATENASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank14
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P14
Within normal range
vs 5Y Ago
-0.5x
Contraction
Streak
2 yr
Consecutive growthDecelerating
PeriodValue
2025-20.13%
2024-21.78%
2023-46.14%
202248.69%
202171.56%
202043.13%
201956.67%
201863.06%
201729.89%
201633.19%